OPM Biosciences receives RMB100m financing from China Life Health Fund

OPM Biosciences has completed a new round of financing of 100 million yuan by China Life Health Fund. The two parties have established a strategic partnership. Haoyue Capital served as the sole financial advisor for this round of financing.

OPM Biosciences has completed a new round of financing of 100 million yuan by China Life Health Fund. The two parties have established a strategic partnership. Haoyue Capital served as the sole financial advisor for this round of financing.

The proceeds will be used to expand the cultivation medium production line and CDMO service platform, introduce talents, and expand overseas business.

Previously, OPM Biosciences had obtained a strategic investment of nearly 100 million yuan from Fortune Capital and China Renaissance.

Established in Shanghai in November 2013, OPM Biosciences is a high-tech enterprise specialized in the development and mass production of serum-free medium for animal cells.

The company’s market share ranks the top in China, and more than 90% are high-end antibody medium. At present, OPM Biosciences serves more than 300 clients, covering multiple top-end pharmaceutical companies and innovative drug development companies.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/06/07/opm-biosciences-receives-rmb100m-financing-from-china-life-health-fund/.

Leave a Reply

Please Login to Comment